Bosentan (Tracleer)

A sulfonamide and pyrimidine derivative that acts as a dual endothelin receptor antagonist used to manage PULMONARY HYPERTENSION and SYSTEMIC SCLEROSIS.

Also Known As:

Tracleer; 4-t-Butyl-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2,2'-bipyrimidin-4-yl)benzenesulfonamide; Bosentan Anhydrous; Bosentan Monohydrate; Ro 47-0203; Ro-47-0203; Ro 47 0203; Ro 470203; Benzenesulfonamide, 4-(1,1-dimethylethyl)-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)(2,2'-bipyrimidin)-4-yl)-

Networked: 1230 relevant articles (221 outcomes, 289 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Dingemanse, Jasper: 18 articles (04/2017 - 04/2002)
2.	Humbert, Marc: 14 articles (01/2021 - 12/2004)
3.	Berger, Rolf M F: 13 articles (01/2021 - 07/2006)
4.	Simonneau, Gérald: 13 articles (03/2014 - 07/2003)
5.	Beghetti, Maurice: 12 articles (01/2021 - 02/2005)
6.	Naeije, Robert: 12 articles (08/2016 - 03/2003)
7.	Clozel, Martine: 12 articles (11/2015 - 03/2002)
8.	Rubin, Lewis J: 12 articles (03/2014 - 01/2002)
9.	Sitbon, Olivier: 12 articles (01/2013 - 07/2003)
10.	Galiè, Nazzareno: 11 articles (11/2016 - 04/2003)

Related Diseases

1.	Pulmonary Arterial Hypertension 06/21/2008 - "Bosentan treatment could be beneficial for patients with WHO FC II pulmonary arterial hypertension." 04/01/2003 - "This study was conducted to investigate the pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. " 07/01/2011 - "Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children." 12/01/2010 - "Bosentan and improved pulmonary endothelial function in pulmonary arterial hypertension." 03/01/2010 - "Data on long-term efficacy of bosentan, an oral dual ET receptor antagonist, in SSc-associated pulmonary arterial hypertension (SSc-PAH) are lacking. "
2.	Pulmonary Hypertension 08/01/2011 - "Bosentan has proven efficacy in pulmonary hypertension in the short term. " 12/01/2006 - "The results of this study suggest that treatment with bosentan is associated with long-term improvement in clinical variables and exercise capacity in approximately two thirds of the patients with pulmonary hypertension." 09/01/2009 - "Long-term efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension." 05/01/2009 - "Duration of right ventricular contraction predicts the efficacy of bosentan treatment in patients with pulmonary hypertension." 07/01/2006 - "The efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension: a 1-year follow-up study."
3.	digital ulcers 01/01/2012 - "These results suggest that bosentan is an effective treatment for refractory digital ulcers associated with SSc; however, liver function should be carefully monitored. " 01/01/2017 - "The safety and tolerability of bosentan was monitored over 52 weeks of study treatment (primary end-point), while incidence and healing of digital ulcers were also assessed up to week 16. " 09/01/2016 - "The study included 30 patients (4 males, 26 females; mean age 49.6±15.4 years; range 23 to 71 years) diagnosed with SSc and treated with bosentan for digital ulcers. " 12/01/2010 - "Double-blind randomized clinical trials are needed to evaluate the effects of bosentan on skin perfusion of SSc patients without PAH and with active digital ulcers." 04/01/2006 - "Forthcoming results from the international RAPIDS-2 study should clarify the indications for bosentan in the treatment of SSc-related digital ulcers."
4.	Systemic Scleroderma (Systemic Sclerosis) 10/01/2011 - "Bosentan is effective against digital ulcerations and hyperkeratosis in systemic sclerosis." 07/01/2015 - "Bosentan blocks the antiangiogenic effects of sera from systemic sclerosis patients: an in vitro study." 12/01/2006 - "Bosentan increases myocardial perfusion and function in systemic sclerosis: a magnetic resonance imaging and Tissue-Doppler echography study." 06/01/2023 - "Real-world effectiveness and safety of bosentan in Japanese patients with systemic sclerosis: A single-center retrospective study." 12/01/2021 - "Novel Use of Bosentan for Postoperative Wound Healing of the Foot in Systemic Sclerosis."
5.	Congenital Heart Defects (Congenital Heart Defect) 11/15/2011 - "The aim of this study was to retrospectively analyze the long-term efficacy and safety of bosentan in adults with PAH secondary to congenital heart disease (PAH-CHD). " 11/01/2006 - "However, there are limited studies examining the benefits of bosentan in PAH associated with congenital heart disease (CHD). " 07/01/2012 - "Bosentan is the only medication to date to be compared with placebo in a randomized controlled trial specifically targeting congenital heart disease-associated PAH. " 05/01/2007 - "To evaluate safety, tolerability, and clinical and haemodynamic effects of bosentan in patients with PAH related to congenital heart disease (CHD). " 09/01/2006 - "Pre-clinical data support the rationale for the potential benefit of bosentan in PAH associated with congenital heart disease (CHD). "

Related Drugs and Biologics

1.	Endothelin Receptor Antagonists
2.	Sildenafil Citrate (Viagra)
3.	Endothelins (Endothelin)
4.	Iloprost (Ventavis)
5.	Epoprostenol (Prostacyclin)
6.	macitentan
7.	ambrisentan
8.	Endothelin-1 (Endothelin 1)
9.	Endothelin A Receptor
10.	Endothelin Receptors (Endothelin Receptor)

Related Therapies and Procedures

1.	Therapeutics
2.	Oral Administration
3.	Renal Dialysis (Hemodialysis)
4.	Drug Therapy (Chemotherapy)
5.	Heart Transplantation (Grafting, Heart)